About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Ophthalmology
›
Top Articles
Ophthalmology
Ophthalmology
7.3
(top 1%)
Impact Factor
8.2
(top 1%)
extended IF
288
(top 1%)
H-Index
4.1K
authors
16.7K
papers
859.3K
citations
8.8K
citing journals
69.2K
citing authors
Most Cited Articles of Ophthalmology
Title
Year
Citations
Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis
2014
2.8K
Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales
2003
1.9K
Grading Diabetic Retinopathy from Stereoscopic Color Fundus Photographs—An Extension of the Modified Airlie House Classification
1991
1.8K
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
2012
1.5K
Prevalence of age-related maculopathy. The Beaver Dam Eye Study
1992
1.5K
Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050
2016
1.4K
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results
2012
1.3K
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE
2012
1.1K
Early Photocoagulation for Diabetic Retinopathy
1991
1.1K
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
2010
1K
Imaging of macular diseases with optical coherence tomography
1995
1K
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
2006
1K
Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group
1991
984
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
2009
978
The Wisconsin age-related maculopathy grading system
1991
967
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema
2011
966
Predictors of long-term progression in the early manifest glaucoma trial
2007
951
Photocoagulation Treatment of Proliferative Diabetic Retinopathy
1981
936
Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study
1999
918
Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study
1995
892
Intravitreal triamcinolone for refractory diabetic macular edema
2002
861
Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery
2001
848
Clinical classification of age-related macular degeneration
2013
830
Limbal autograft transplantation for ocular surface disorders
1989
812
Survey of 520 eyes with uveal metastases
1997
802
previous
2011
2012
2013
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.